Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Ocuphire Pharma Inc OCUP

Healthcare
Ocuphire Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. The Company’s lead retinal product candidate, APX3330, is a small-molecule inhibitor of Ref-1 (reduction oxidation effector factor-1 protein). Ref1 is a regulator of transcription factors such as HIF-1a... see more

Recent & Breaking News (NDAQ:OCUP)

Rexahn Pharmaceuticals Receives Notice of Allowance for A New U.S. Patent Covering the Use of RX-5902 (Supinoxin™)

GlobeNewswire January 29, 2018

Rexahn Pharmaceuticals Announces Poster Presentation of RX-3117 Data in Metastatic Pancreatic Patients at the American Society of Clinical Oncology Gastrointestinal Cancers (ASCO GI) 2018 Annual Meeting

GlobeNewswire January 22, 2018

Rexahn Pharmaceuticals to Present at the American Society of Clinical Oncology Gastrointestinal Cancers (ASCO GI) 2018 Annual Meeting

GlobeNewswire January 18, 2018

Rexahn Pharmaceuticals to Present at Biotech Showcase™ 2018

GlobeNewswire January 8, 2018

Rexahn Pharmaceuticals Announces the Appointment of Douglas J. Swirsky as President and Chief Financial Officer

GlobeNewswire January 4, 2018

Rexahn Pharmaceuticals Presents New Preclinical Data on Supinoxin™ at the 2017 San Antonio Breast Cancer Symposium

GlobeNewswire December 11, 2017

Rexahn Pharmaceuticals to Present at the Stifel 2017 Healthcare Conference

GlobeNewswire November 9, 2017

Rexahn Pharmaceuticals Issues Mid-Year Shareholder Letter to Review Recent Progress and Clinical Plans

GlobeNewswire August 14, 2017

Rexahn Pharmaceuticals Reports Second Quarter 2017 Financial and Operational Results

GlobeNewswire August 7, 2017

Today's Research Report Coverage on Biotech Stocks -- Rexahn Pharma, Protalix BioTherapeutics, Navidea Biopharma, and Biostage

PR Newswire July 19, 2017

Rexahn Pharmaceuticals Receives Notice of Allowance for a New U.S. Patent Covering the Use of RX-3117

GlobeNewswire July 10, 2017

Rexahn Announces $10 Million Registered Direct Offering

GlobeNewswire June 7, 2017

Rexahn Pharmaceuticals Presents Preliminary Efficacy Data from the Ongoing Phase IIa Clinical Trial of RX-3117 in Metastatic Bladder Cancer at the American Society of Clinical Oncology (ASCO) 2017 Annual Meeting

GlobeNewswire June 4, 2017

Mid-Morning Market Update: Markets Edge Hogher; Lululemon Beats Q1 Estimates

Benzinga.com  June 2, 2017

Biotech Stocks Under Scanner -- Rexahn Pharma, Peregrine Pharma, Immunomedics, and Protalix BioTherapeutics

PR Newswire May 8, 2017

Biotech Stocks Under Scanner -- Rexahn Pharma, Northwest Biotherapeutics, Celldex Therapeutics, and Vertex Pharma

PR Newswire March 31, 2017

How These Biotech Stocks are Faring? -- Agenus, Tokai Pharma, Eleven Biotherapeutics, and Rexahn Pharma

PR Newswire February 14, 2017

Rexahn Pharmaceuticals to Present at the 2nd Annual Disruptive Growth & Healthcare Conference

Accesswire February 6, 2017

Rexahn Pharmaceuticals to Present at Biotech Showcase™ 2017

GlobeNewswire January 3, 2017

Rexahn Pharmaceuticals Reports Third Quarter 2016 Financial Results and Provides Corporate Update

GlobeNewswire November 7, 2016